BioCentury
ARTICLE | Company News

Calithera, Incyte deal

February 3, 2017 8:35 PM UTC

Calithera granted Incyte exclusive, worldwide rights to CB-1158 for hematology and cancer indications. The arginase 1 (ARG1) and ARG2 inhibitor is in a Phase I/II trial to treat advanced or metastatic solid tumors, with data expected this year. The companies plan to evaluate CB-1158 in combination with other immuno-oncology agents, which Incyte said may include an anti-PD-1 therapy or Incyte’s epacadostat. Epacadostat is an indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor...